**WM STUDY NOW ENROLLING!**

# Are You Living with Waldenström Macroglobulinemia (WM)?

## WM clinical research study seeks volunteers

Clinical research studies help researchers learn about potential treatments, called investigational or study drugs. A clinical research study, or clinical trial, is now enrolling people living with Waldenström Macroglobulinemia (WM) who have a CXCR4 genetic variant, or mutation. People with the CXCR4 variant do not respond as well to existing BTK inhibitor treatments for WM, such as Imbruvica® (ibrutinib).[1]

## About the study

This clinical research study will help researchers answer questions about the study drug, which is called mavorixafor.

Mavorixafor is an investigational oral medication taken as a capsule.

This is a Phase 1b study, which means researchers want to know what dosage of mavorixafor, (the study drug) is safe.

The study drug will be taken in combination with ibrutinib, an FDA-approved treatment for WM.

The study is being conducted as part of a collaboration with The Leukemia & Lymphoma Society to help advance the development of mavorixafor for the treatment of WM.

## Who can join?

- Adults age 18+
- WM diagnosis with MYD88 and CXCR4 genetic variants
- You may need to meet more criteria in order to join the study. To learn more, visit ClinicalTrials.gov and search for NCT04274738

## Why participate in a clinical study?

- More treatment options are needed for people living with WM.
- People who join this clinical study may help researchers understand more about WM and potential treatments.
- Clinical studies are required to make sure a medicine is safe and works before it is approved by the FDA as a treatment option.
- There is no cost to join the study, and expenses for medical care and travel are reimbursed by X4 Pharmaceuticals, the study sponsor.

**LEARN MORE**

**Talk** to your doctor to find out if this study is a good option for you.

**Email** patientinfo@x4pharma.com


### References

1. Castillo JJ, Xu L, Gustine JN, et al. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib. Br J Haematol. 2019;187(3):356-363. doi:10.1111/bjh.16088


*Search ClinicalTrials.gov for NCT04274738*

X4 PHARMACEUTICALS